The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,626
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology
Deli, M. A., Ábrahám, C. S., Kataoka, Y., & Niwa, M. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1377-8 · Cited by 643
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599
Physicochemical Profiling (Solubility, Permeability and Charge State)
Avdeef, A. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013395100 · Cited by 587
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Waterhouse, R. (2003) · Molecular Imaging & Biology · doi:10.1016/j.mibio.2003.09.014 · Cited by 567
Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard
Oldendorf, W. H. (1970) · Brain Research · doi:10.1016/0006-8993(70)90123-x · Cited by 548
ABC Transporters and the Blood-Brain Barrier
Begley, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384844 · Cited by 545
An in situ brain perfusion technique to study cerebrovascular transport in the rat
Takasato, Y., Rapoport, S. I., & Smith, Q. R. (1984) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1984.247.3.h484 · Cited by 541
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).
Prentis, R., Lis, Y., & Walker, Sr. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03318.x · Cited by 471
Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation
Abbott, N. J. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1374-y · Cited by 469
Benzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 450
Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat
Ohno, K., Pettigrew, K. D., & Rapoport, S. I. (1978) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1978.235.3.h299 · Cited by 444
Doran, A., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Sneader, W. (2005) · Wiley eBooks · doi:10.1002/0470015535 · Cited by 427
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
In vitro models for the blood–brain barrier
Garberg, P., Ball, M., Borg, N., Cecchelli, R., Fenart, L., Hurst, R. D., Lindmark, T., Mabondzo, A., Nilsson, J. E., Raub, T. J., et al. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2004.06.011 · Cited by 394
Knockouts model the 100 best-selling drugs—will they model the next 100?
Zambrowicz, B. P., & Sands, A. T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd987 · Cited by 393
The human brain and spinal cord
Clarke, E., & O'Malley, C. D. (1968) · University of California Press eBooks · Cited by 388
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrier
Wang, Q., Rager, J. D., Weinstein, K., Kardos, P. S., Dobson, G. L., Li, J., & Hidalgo, I. J. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.10.007 · Cited by 348
The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery
Lin, J., Sahakian, D., de Morais, S., Xu, J., Polzer, R., & Winter, S. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452096 · Cited by 327
Principles and Practice of Geriatric Medicine
(2005) · Wiley eBooks · doi:10.1002/047009057x · Cited by 303
Sneader, W. (2005) · Cited by 302
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 302
Sertraline Treatment of Pathological Gambling: A Pilot Study
Saiz-Ruiz, J., Blanco, C., Ibáñez, A., Masramon, X., Gómez, M. M., Madrigal, M., & Díez, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0104 · Cited by 293
SHEN, D., ARTRU, A., & ADKISON, K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.011 · Cited by 286
Sacco, R. L., DeRosa, J. T., Haley, Jr., Levin, B., Ordronneau, P., Phillips, S. J., Rundek, T., Snipes, R. G., Thompson, J. L. P., & for the GAIN Americas Investigators (2001) · JAMA · doi:10.1001/jama.285.13.1719 · Cited by 283
Progress in the reduction, refinement and replacement of animal experimentation
Balls, M., van Zeller, A.-M., & Halder, M. (2000) · Elsevier eBooks · Cited by 280
Methodological issues in microdialysis sampling for pharmacokinetic studies
de Lange, E. C. M., de Boer, A. G., & Breimer, D. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00107-1 · Cited by 264
ADME/PK as part of a rational approach to drug discovery
Eddershaw, P. J., Beresford, A. P., & Bayliss, M. K. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01540-3 · Cited by 237
DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00001 · Cited by 233
How to measure drug transport across the blood-brain barrier
Bickel, U. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.15 · Cited by 213
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Gründer, G., Carlsson, A., & Wong, D. F. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.10.974 · Cited by 199
The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Hoyte, L., Barber, P., Buchan, A., & Hill, M. (2004) · Current Molecular Medicine · doi:10.2174/1566524043479248 · Cited by 190
New approaches to in vitro models of blood–brain barrier drug transport
Terasaki, T., Ohtsuki, S., Hori, S., Takanaga, H., Nakashima, E., & Hosoya, K.-I. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02858-7 · Cited by 162
Applications of high-throughput ADME in drug discovery
Kassel, D. B. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.015 · Cited by 152
A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
An Overview of In Vitro Techniques for Blood-Brain Barrier Studies
Reichel, A., Begley, D. J., & Abbott, N. J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-419-0:307 · Cited by 140
Anxioselective Compounds Acting at the GABAA Receptor Benzodiazepine Binding Site
Atack, J. R. (2003) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007033482841 · Cited by 128
Excitatory amino acid antagonists for acute stroke
Muir, K. W., & Lees, K. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001244 · Cited by 124
(2022) · Acta Neurologica Scandinavica · doi:10.1111/(issn)1600-0404 · Cited by 120
Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Björner, A., Mannaert, E., Remmerie, B., Eerdekens, M., & Nyberg, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004924 · Cited by 119
Pharmacotherapy for Alzheimer's disease: progress and prospects
Palmer, A. M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02056-4 · Cited by 118
Self-citationThe human brain and spinal cord
Clarke, E. (1968) · Cited by 116
Riley, R. J., Parker, A. J., Trigg, S., & Manners, C. N. (2001) · Pharmaceutical Research · doi:10.1023/a:1011085411050 · Cited by 114
Increased dopamine release in the human amygdala during performance of cognitive tasks
Fried, I., Wilson, C. L., Morrow, J. W., Cameron, K. A., Behnke, E., Ackerson, L. C., & Maidment, N. T. (2001) · Nature Neuroscience · doi:10.1038/84041 · Cited by 114
Green, A., & Ashwood, T. J. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007053544156 · Cited by 114
In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind”
Goodwin, J. T., & Clark, D. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075705 · Cited by 113
Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model
Gombar, V. K., Polli, J. W., Humphreys, J. E., Wring, S. A., & Serabjit‐Singh, C. J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20035 · Cited by 112
Snyder, S. H. (1996) · DigitalGeorgetown (Georgetown University Library) · Cited by 110
The GABAA receptor gene family: new opportunities for drug development.
Whiting, P. J. (2003) · PubMed · Cited by 109
Factors affecting delivery of antiviral drugs to the brain
Strazielle, N., & Ghersi‐Egea, J. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.454 · Cited by 107
Drug metabolism and pharmacokinetics in drug discovery.
Roberts, S. A. (2003) · PubMed · Cited by 95
Molecular, Functional and Biochemical Characteristics of the Dopamine Transporter
Hitri, A., Hurd, Y. L., Wyatt, R. J., & Deutsch, S. I. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199402000-00001 · Cited by 94
In Silico Prediction Models for Blood-Brain Barrier Permeation
Ecker, G. F., & Noe, C. R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365071 · Cited by 86
Assessment of Blood-Brain Barrier Penetration: In Silico, In Vitro and In Vivo
Feng, B. S. P. M. R. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337063 · Cited by 86
Jorajuria, S., Dereuddre‐Bosquet, N., Bécher, F., Martin, S., Porcheray, F., Garrigues, A., Mabondzo, A. M., Bénech, H., Grassi, J. J., Orlowski, S., et al. (2004) · Antiviral Therapy · doi:10.1177/135965350400900403 · Cited by 85
Computational models to predict blood–brain barrier permeation and CNS activity
Subramanian, G., & Kitchen, D. B. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/b:jcam.0000017372.32162.37 · Cited by 73
Dawson, D. A., Wadsworth, G., & Palmer, A. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03269-8 · Cited by 72
Self-citationWalker, M. C., Tong, X., Perry, H., Alavijeh, M. S., & Patsalos, P. N. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703337 · Cited by 71
Self-citationBergström, C. A. S. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960303.x · Cited by 71
(2004) · PubMed · Cited by 66
Deane, R., & Bradbury, M. W. B. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02337.x · Cited by 64
Drug delivery and in vitro models of the blood-brain barrier.
Cucullo, L., Aumayr, B., Rapp, E., & Janigro, D. (2005) · PubMed · Cited by 61
Drugs in development for Parkinson's disease.
Johnston, T. H., & Brotchie, J. M. (2004) · PubMed · Cited by 52
Principles and practice of geriatric medicine
Overstall, P. W. (1986) · Health Policy · doi:10.1016/0168-8510(86)90031-x · Cited by 50
Recent advances in P450 research
Raucy, J. L., & Allen, S. W. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500044 · Cited by 50
Scott‐Stevens, P., Atack, J. R., Sohal, B., & Worboys, P. D. (2004) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.423 · Cited by 50
Elsinga, P. H., Hendrikse, N. H., Bart, J., van Waarde, A., & Vaalburg, W. (2004) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0951-x · Cited by 47
Which in vitro Screens Guide the Prediction of Oral Absorption and Volume of Distribution?
Waterbeemd, H. V. D. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960304.x · Cited by 43
The Influence of DMPK as an Integrated Partner in Modern Drug Discovery
Riley, R. J., Martin, I. J., & Cooper, A. E. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337135 · Cited by 42
Schneider, L. S. S., Olin, J. T., Novit, A., & Luczak, S. E. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000359 · Cited by 42
Wang, X., Ratnaraj, N., & Patsalos, P. N. (2004) · Seizure · doi:10.1016/j.seizure.2004.01.007 · Cited by 42
Therapeutic receptor-blocking concentrations of neuroleptics
Seeman, P. M. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00002 · Cited by 38
Patsalos, P. N., Alavijeh, M. S., Semba, J., & Lolin, Y. I. (1992) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/1056-8719(92)90061-5 · Cited by 32
Self-citationAtack, J. R., Alder, L., COOK, S., SMITH, A., & McKernan, R. M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.004 · Cited by 29
Physicochemical Profiling (Solubility, Permeability and Charge State)
Avdeef, A. (2004) · Frontiers in Medicinal Chemistry - Online · doi:10.2174/1567204043396604 · Cited by 26
CNS drug discovery: challenges and solutions.
Palmer, A. M., & Stephenson, F. A. (2005) · PubMed · Cited by 22
Self-citationPatsalos, P. N., Abed, W. T., Alavijeh, M. S., & O’Connell, M. T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16362.x · Cited by 22
Self-citation
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426
A Review on Central Nervous System Effects of Gastrodin
Liu, Y., Gao, J., Peng, M., Meng, H., Ma, H., Cai, P., Xu, Y., Zhao, Q., & Si, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00024 · Cited by 387
Liu, H., Wang, J., Zhou, W., Wang, Y., & Yang, L. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.02.004 · Cited by 326
Metadata
- Authors
- Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M.
- Venue
- NeuroRX
- Published
- 2005-10
- Volume
- 2
- Issue
- 4
- Pages
- 554-571
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2118857937
- Cited by
- 497
- References
- 89
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.